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Rheumatoid arthritis (RA) is one of the major autoimmune diseases of global prevalence. The use of the anti-inﬂammatory drugs
for the treatment of RA is associated with severe adverse reactions and toxicity. This limitation has necessitated the search for
novel therapeutic products. We report here a traditional Chinese medicine-based herbal formula, Huo luo xiao ling dan (HLXL),
which has potent antiarthritic activity as validated in the rat adjuvant-induced arthritis (AA) model. HLXL (2.3g/Kg) was fed
to Lewis (RT.11) rats daily by gavage beginning at the onset of arthritis and then continued through the observation period.
HLXL inhibited the severity of ongoing AA. This suppression of arthritis was associated with signiﬁcant alterations in the T cell
proliferative and cytokine responses as well as the antibody response against the disease-related antigen, mycobacterial heat-shock
protein 65 (Bhsp65). There was a reduction in the level of the proinﬂammatory cytokines IL-17 and IL-1β but enhancement of
the anti-inﬂammatory cytokine IL-10 level. In addition, there was inhibition of both the anti-Bhsp65 antibody response and the
serum level of nitric oxide. Thus, HLXL is a promising CAM modality for further testing in RA patients.
1.Introduction
Rheumatoid arthritis (RA) is one of the major human
autoimmune diseases aﬀecting about 1 per cent of the
adult population [1, 2]. The disease is characterized by
inﬂammation of the synovial tissue and damage to the
cartilage and bone of the joints, leading to severe deformities
[1, 3–5]. The precise etiologic agent in RA is not yet deﬁned.
The drugs that inhibit inﬂammatory reactions are a vital
component of the therapeutic arsenal against RA [1, 6, 7].
However, the adverse reactions and toxicity associated with
the use of these drugs have expeditiously promoted the
use of natural plant products or procedures belonging to
the diverse traditional systems of medicine by patients with
RA [8–14] and other chronic inﬂammatory disorders [15–
23]. This growing trend warrants a continuous search for
new natural antiarthritic complementary and alternative
medicine (CAM) products with well-deﬁned mechanisms of
action.
Traditional Chinese medicine (TCM) oﬀers a variety of
herbal CAM products that have been used in the treatment
of patients with chronic inﬂammatory disorders for several
decades [8–19]. However, many of these products have not
been validated experimentally for their composition and/or
mechanismofaction.Huoluoxiaolingdan(HLXL),aTCM-
based Chinese herbal formula, has been in use in China
for the treatment of patients with a variety of disorders,
including arthritis [24, 25]. We have previously reported that2 Evidence-Based Complementary and Alternative Medicine
HLXL consisting of 11 herbs has anti-inﬂammatory activity
as evident upon testing in an experimental model of paw
edema [24, 25]. In this study, based on the rat adjuvant-
induced arthritis (AA) model of human RA [26, 27], we
report the immunological basis of the therapeutic eﬀect of
HLXL against autoimmune arthritis.
AA can be induced in Lewis (LEW) rats (RT.1l)b y
immunization with heat-killed M. tuberculosis H37Ra (Mtb)
in oil [26–28]. The mycobacterial heat-shock protein 65
(Bhsp65) is one of the major antigenic targets of the T cell
response of arthritic rats [28–31]. Our results show that
HLXL suppresses the severity of ongoing inﬂammatory AA.
Furthermore, this antiarthritic activity of HLXL is associated
with changes in both the T cell and the antibody responses
against Bhsp65. Also altered was the level of serum nitric
oxide (NO), a biochemical mediator of inﬂammation. We
suggest that HLXL be considered for further evaluation of its
eﬃcacy as a CAM modality for the treatment of RA patients.
2.MaterialsandMethods
2.1. Animals. Male, 5- to 6-week-old Lewis (LEW/Hsd)
(RT.1l) rats purchased from Harlan Sprague-Dawley (HSD)
(Indianapolis, IN, USA) were used in this study. This study
protocol was approved by the University of Maryland School
of Medicine, Baltimore (UMB) and Institutional Animal
Care Use Committee (IACUC). The IACUC guidelines fol-
low the Public Health Service (PHS) Policy on Humane Care
and Use of Laboratory Animals and the National Research
Council Guide for the Care and Use of Laboratory Animals.
Furthermore, UMB is fully accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care
(AAALAC) International.
2.2. Antigens. Recombinant mycobacterial heat-shock pro-
tein 65 (Bhsp65) was prepared as described elsewhere [32].
Ovalbumin (Ova) was obtained from Sigma-Aldrich (St.
Louis, MO), and puriﬁed protein derivative (PPD) was
purchased from Mycos Research (Fort Collins, CO).
2.3. Induction and Evaluation of Adjuvant Arthritis (AA). AA
wasinducedinLEWratsbys.c.injectionatthebaseofthetail
of 1mg/rat heat-killed M. tuberculosis H37Ra (Mtb) (Difco,
Detroit, MI) in 200 µL of mineral oil (Sigma-Aldrich). The
severity of arthritis was graded on the basis of erythema
and swelling as previously described [32, 33]. The highest
score for each paw was 4, and the total maximum score for
each rat was 16. The natural course of AA includes 4 phases:
incubation (d 0–8), onset (d 9–11), peak (d 17–19), and
recovery (d 21–26).
2.4. Histopathological Evaluation of Hind Paw Joints of Rats.
Hind paws of rats were harvested, skinned, and ﬁxed for 3–
7 days with 10% phosphate-buﬀered formalin (Fisher Sci-
entiﬁc, Fair Lawn, NJ). Thereafter, the paws were decalciﬁed
in formic acid (Fisher Scientiﬁc), embedded in paraﬃn, and
sectioned longitudinally (820 Microtome, Fisher Scientiﬁc).
Tissuesections(5-μm)weremountedonaglassslide,stained
with hematoxylin-eosin (Sigma-Aldrich), and assessed for
morphological changes and cellular inﬁltrates [34].
2.5. Composition, Characterization, and Toxicity of the CAM
Modality, HLXL. The composition of the herbal formula
huo luo xiao ling dan (HLXL), the method for its prepa-
ration, and the assessment of toxicity of HLXL have been
described previously [24, 25]. The following 11 herbs com-
prise HLXL: Ruxiang (Boswellia carterii Birdw.), Qianghuo
(Notopterygium incisum Ting ex H.T. Chang), Danggui
(Angelica sinensis (Oliv.) Diels), Baishao (Paeonia lacti-
ﬂora Pall.), Gancao (Glycyrrhiza uralensis Fisch.), Yanhusuo
(Corydalis yanhusuo W.T. Wang.), Danshen (Salvia miltior-
rhiza Bge.), Chuanxiong (Ligusticum chuanxiong S.H. Qiu.),
Qinjiao(GentianamacrophyllaPall.),Guizhi(Cinnamomum
cassia Presl.), and Duhuo (Angelica pubescens Maxim.). The
details of the acquisition, authentication, purity, processing,
and extraction of the individual herbs, HPLC ﬁngerprinting
of HLXL mixture, information on voucher samples and
pharmacopoeia, and toxicity are described elsewhere [24,
25]. The toxicity of HLXL was assessed by daily feeding
of HLXL to LEW rats for 6 consecutive weeks and then
observing these rats regularly forunusual behavioral changes
and standard signs and symptoms of toxicity [25]. Blood
biochemistry as well as full necropsy and histopathological
examination of tissues was also performed to assess toxicity.
The control rats were fed with vehicle instead of HLXL.
Taking all these parameters together, no adverse reactions or
toxicity of HLXL were observed either at 2.3 or 4.6g/kg [25].
2.6. Treatment of Rats with HLXL. The rats were randomly
divided into three groups following the onset of arthritis on
day 11 after Mtb injection. The experimental group of rats
was fed HLXL (2.3g/kg) daily by gavage beginning on day
12 after Mtb injection and then continued throughout the
course of AA. This dose was selected after a pilot study in
which 3 doses (g/kg) of HLXL were tested: 1.15, 2.3, and
4.6. The control group of rats received the vehicle (water) by
gavage on the corresponding days. A third group of arthritic
rats was fed methotrexate (MTX) (Sigma) (0.5mg/kg), an
established antiarthritic compound, as a positive control. All
these rats were observed regularly for signs of arthritis.
2.7. Lymph Node Cell (LNC) Proliferation Assay. The drain-
ing lymph nodes (inguinal, iliac, and popliteal) of rats were
harvested on day 7 after the initiation of HLXL feeding. A
single-cell suspension of lymph node cells (LNCs) from rats
of the respective group (experimental versus control) was
prepared separately and then cultured (5×105 cells/well of
a 96-well plate) in serum-free HL-1 medium (BioWhittaker,
Walkersville, MD). The cells were plated in replicates (n=4)
and cultured with antigen for 2 days as described in detail
elsewhere [33, 35]. Thereafter, 3[H]-thymidine (1μCi/well)
was added to these LNCs and the cells cultured for another
16h [33, 35], and then the cells were harvested onto a
printed glass ﬁber ﬁlter. The incorporation of radioactivity
inproliferatingcellswasmeasuredusingaliquidscintillation
counter. The results were expressed either as counts perEvidence-Based Complementary and Alternative Medicine 3
minute (cpm) or as a stimulation index (the ratio of cpm
in the presence of antigen and cpm of cells in medium
alone). Bhsp65 (6.5μg/ml) was used as the test antigen,
while PPD (30μg/ml) and Ova (40μg/ml) served as positive
and negative controls, respectively. The indicated optimal
concentrations of diﬀerent antigens used were selected after
dose titrations in preliminary experiments.
2.8. Isolation of Synovium-Inﬁltrating Cells (SIC) and the
Preparation of Cell Lysate. The ankle region of an arthritic
rat was nicked in the metatarsal area. After removal of the
skin and superﬁcial tendons, the articular cavity was opened
up from the lateral side. Thereafter, the synovial tissue was
dissected out into the culture medium placed in a petri
dish. This dissected tissue was digested for 1h at 37◦Ci n
Hanks’ balanced salt solution (HBSS) containing 3mg/mL
collagenase 1A (Sigma-Aldrich), 3mg/mL hyaluronidase IV-
S 1mg/mL (Sigma), 0.1mg/mL DNase II (Sigma), 1% fetal
bovine serum (FBS) (Invitrogen), and 5% HEPES (EM
Science). The digested tissue was then ﬁltered through a
nylon mesh and washed extensively with PBS. The collected
cells were lysed in 250μll y s i sb u ﬀer (Bio-rad), and the
supernate was harvested for testing of cytokine levels.
2.9. Testing of the Cytokine Response
(A) Quantitative Real-Time Polymerase Chain Reaction (qRT-
PCR). The LNCs were restimulated with antigen for 48h as
in an LNC proliferation assay. The total RNA extracted from
these LNCs was reverse-transcribed to cDNA and then tested
inqRT-PCRusingspeciﬁcprimersforthegenesencodingthe
ratIFN-γ,IL-10,andIL-17employingplatinumSYBRGreen
[36, 37]. The levels of cytokine mRNA were normalized to
thatofthehypoxanthine-guanine phosphoribosyltransferase
gene (hprt), and the results were presented as the relative
gene expression levels.
(B) Enzyme-Linked Immunosorbent Assay (ELISA). The
supernates of lysed synovium-inﬁltrating cells (SIC) were
assayed by ELISA for TNF-α and IL-1β in the cytokine core
facility of UMB. The cytokine levels were normalized to
the total protein content which was measured by Bio-Rad
Protein Assay (Bio-Rad Laboratories, Hercules, CA).
2.10. Measurement of the Level and Isotype of Anti-Bhsp65
Antibodies. The sera of the test and control group of rats
(n = 3 each) were added at a dilution of 1:100 each to
antigen-coated wells (100ng/well) of a high-binding ELISA
plate (Greiner Bio-One) [35, 38]. The plate was incubated
for 1h at room temperature, and then the wells were washed
thoroughly. The plate-bound total Ig or the IgG1/IgG2a
isotype was detected by using the appropriate horseradish
peroxidase-conjugated goat antirat antibodies (Zymed). The
color intensity was read as optical density (O.D.) at 450
nm using a Vmax ELISA autoreader (Molecular Devices)
[35, 38].
2.11. Determination of the Serum Nitric Oxide (NO) Levels.
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Figure 1: HLXL feeding reduced the progression and severity of
ongoing AA in the LEW rat. Arthritic LEW rats were fed by gavage
daily with HLXL (2.3g/kg body weight, experimental group), water
(negative control group), or MTX (0.5mg/kg, positive control
group), from day 12 to day 23 after Mtb immunization. Rats were
observed regularly throughout the course of AA. Arthritic scores
(mean±SEM) (a) of a representative experiment (n = 4 per group)
are shown. The days of signiﬁcant diﬀerence in the arthritic scores
of HLXL/MTX group versus the control are marked (∗, P<. 05; ∗∗,
P<. 01). Also shown are representative hind paw histopathology
sections of water-fed control (b) and HLXL-fed (c) rats on day 18.
were assessed by measuring the nitrite (NO
−
2 ) and nitrate
(NO
−
3 ) content using a colorimetric assay kit (Biovision
research products, Mountain View, CA) [34]. The results
were expressed as mM.
2.12. Statistical Analysis. T h ed a t aw e r ee x p r e s s e da sm e a n
± SEM. Student’s t-test and two-way ANOVA were used
to assess the signiﬁcance of diﬀerences using GraphPad
Prism version 4.0. A P-value less than .05 was considered
signiﬁcant.
3. Results
3.1. Attenuation of the Severity of Established Adjuvant
Arthritis in HLXL-Fed LEW Rats. The signs of inﬂammatory4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Alteration of the T cell proliferative and cytokine responses of HLXL-treated arthritic rats. LNCs of arthritic rats harvested on
d 7 after initiation of the daily feeding of HLXL or water were tested for their T cell proliferative (a) and cytokine response (b)–(d) to
antigenic restimulation with Bhsp65 in vitro. Ova served as the control antigen. The results of the proliferation assay were expressed as mean
stimulation index (SI) ± SEM. The cpm value for PPD was 9,240 (the control group) and 5,577 (HLXL group). For cytokines, the level of
mRNA for IL-17 (b), IFN-γ (c), and IL-10 (d) was measured by qRT-PCR, normalized to HPRT expression, and compared with that of cells
in medium. The results of a representative experiment (n = 3 per group) are shown. The data are expressed as “fold relative to cells in the
medium”. (∗, P<. 05; ∗∗, P<. 01).
arthritis appeared about 10 days after Mtb injection of
the LEW rats. Accordingly, HLXL, MTX, or water was
administered daily to rats from day 12 to day 23 of Mtb
injection. The results (Figure 1(a)) show that both the
HLXL-fed and the MTX-fed LEW rats had signiﬁcantly
reduced arthritic scores compared to that of the water-fed
control rats. The reduction in the severity of arthritis was
signiﬁcant between day 16 and day 20 (P<. 01 at day 16 and
day 18, P<. 05 at day 20) for the HLXL group (test group),
and between day 14 and day 20 (P<. 01 at day 14, day 16 and
18, P<. 05 at day 20) for the MTX group (positive control
group). However, the suppressive eﬀect of HLXL on arthritis
was relatively less marked than that of MTX (P<. 01 at day
16, P<. 05 at day 16). Histopathological analyses of the hind
paws showed that on day 18, the extent of the inﬂammatory
cell inﬁltration as well as bone and cartilage destruction was
much less in HLXL-fed rats (Figure 1(c)) than that in the
c o n t r o lr a t s( Figure 1(b)).Evidence-Based Complementary and Alternative Medicine 5
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Figure 3: HLXL inhibited the antibody response to Bhsp65 of LEW rats with AA. Blood samples were collected from experimental (HLXL-
fed)andcontrol(water-fed)groupsofrats(n = 3pergroup)attheindicatedtimepoints,andthentheseraweretestedatadilutionof1:100
each by ELISA for total Ig (a) and IgG2a (b). The results were expressed as optical density (O.D.) at 450nm (mean±SEM). (∗P<. 05).
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Figure 4: Treatment with HLXL suppressed IL-1β production by the synovium-inﬁltrating cells of arthritic rats. The levels of IL-1β (a) and
TNF-α (b) in SIC harvested from the water-fed and HLXL-treated rats (n = 3 per group) on d 19 after Mtb injection were determined by
ELISA. The results were expressed as pg/mg. (∗P<. 05).
3.2. HLXL Diminished the T Cell Proliferative Response
and Deviated the Cytokine Response to Bhsp65 in Arthritic
LEW Rats. We next investigated the immunological changes
associated with the decreased severity of AA following HLXL
treatment. We tested the Bhsp65-speciﬁc proliferative and
cytokine responses of the draining LNCs of arthritic LEW
rats. The HLXL-fed rats showed a signiﬁcantly (P<. 001)
reduced T cell proliferative response to Bhsp65 compared to
that of the control rats (Figure 2(a)). Furthermore, HLXL
feeding suppressed the proinﬂammatory IL-17 (Figure 2(b))6 Evidence-Based Complementary and Alternative Medicine
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Figure 5: The inﬂuence of HLXL on the level of serum NO in
arthritic LEW rats. Sera were obtained from HLXL-fed and water-
fed rats (n = 3 per group) on the indicated days as described
under Materials and Methods. The level of NO in these samples was
determined by a colorimetric assay. The results were presented as
mM (mean ± SEM). (∗P<. 05).
(P<. 01), but increased both the anti-inﬂammatory IL-10
(Figure 2(d)) and the proinﬂammatory IFN-γ (Figure 2(c))
production.
3.3. Suppression of the Antibody Response in Rats Treated with
HLXL. We also measured the serum levels of total Ig as well
as isotype-speciﬁc IgG2a and IgG1 anti-Bhsp65 antibodies
at diﬀerent time points after the onset of arthritis. The
levels of both the total immunoglobulins (Ig) and the IgG2a
antibodies against Bhsp65 in HLXL-fedats versus the levels
of the respective antibody type in the water-fed controls were
comparable on d 11, but signiﬁcantly lower on d 19 (P<. 01
for total Ig, P<. 05 for IgG2a) (Figures 3(a) and 3(b)).
The level of IgG1 was barely above the background (data not
shown).
3.4. HLXL-Mediated Reduction in the Level of IL-1β in the
Target Organ-Inﬁltrating Cells in Arthritic Rats. To study
the HLXL-induced in vivo modulation of the inﬂammatory
response, the SICs were collected from the joints of HLXL-
fed rats and water-fed rats on d 19 after Mtb injection
and then tested for cytokine secretion. HLXL treatment
signiﬁcantly inhibited IL-1β levels by 42% (P<. 001), but
without any change in the level of TNF-α compared to that
of the water-fed group (Figure 4).
3.5.RatsTreatedwithHLXLRevealedReducedLevelsofSerum
Nitric Oxide (NO). Sera of HLXL-fed rats showed reduced
level of NO at d 19 (P<. 05) (Figure 5), and this reduction
in NO level showed an association with a reduction in the
severity of arthritis.
4. Discussion
The results of this study, based on the rat AA model,
have revealed that HLXL, a traditional Chinese medicine-
based herbal formula, can suppress the ongoing disease. The
antiarthritic activity of this CAM modality was associated
with signiﬁcant changes in the T cell proliferative and
cytokine proﬁle of the draining lymph node cells (LNCs),
thecytokinesecretionbythesynovialtissue-derivedcells,the
antibody response to Bhsp65, and the level of serum nitric
oxide (NO).
Arthritic LEW rats raise T cell response to Bhsp65 during
the course of AA [28–32]. The Mtb-primed pathogenic T
cells include subsets of T cells reactive against Bhsp65 [27,
39, 40]. It is conceivable that an antiarthritic compound
might limit the development of arthritis in part by reducing
the activation and expansion of Bhsp65-reactive T cells. In
fact, HLXL-fed LEW rats showed reduced T cell proliferative
response to Bhsp65 compared to the control water-fed rats.
In addition, HLXL feeding induced a signiﬁcant alteration
in the cytokine response of Bhsp65-reactive T cells that
facilitated the inhibitory eﬀect of the herbal mixture on
inﬂammatory arthritis. The majority of the literature on AA
is based on Th1 type of arthritogenic response [27, 39].
Accordingly, a Th2 type of response would be counter-
regulatory for the Th1 type of response [41–43]. In addition,
in the last decade, the role of IL-17 in the pathogenesis
of arthritis is increasingly being realized [44–46] through
studies in the animal models of arthritis, including AA
[37, 47–49]a sw e l la sp a t i e n t sw i t hR A[ 50–52]. In view
of the above cytokine-mediated events in the pathogenesis
of autoimmune arthritis, it is anticipated that a potential
antiarthritic compound might skew the cytokine milieu
towards a predominantly anti-inﬂammatory type [41–43,
46]. This can be achieved by enhancing the Th2 response
and/or reducing the pathogenic Th1/Th17 response. Our
results showed that feeding of HLXL to arthritic LEW rats
indeed enhanced the Th2 (IL-10) response and concomi-
tantly reduced the Th17 (IL-17) response. However, there
alsowasanunexpectedincreaseintheTh1(IFN-γ)response.
This cytokine balance was unanticipated in the context
of the Th1-Th2 paradigm of cytokine-based regulation
[41–43, 46], which would have predicted a reduced IFN-
γ coupled with an enhanced IL-10 leading to deviation
of the cytokine response to a predominantly Th2 type.
Nevertheless, the observed increase in IFN-γ matched with
the concurrent reduction in IL-17. It has been reported by
other investigators that IFN-γ can downregulate the IL-17
response [45, 49]. Similarly, a study from our laboratory
also revealed that tolerization with Bhsp65 reduced IL-17
production but enhanced IFN-γ response [37], supporting
the idea of IFN-γ-mediated regulation of IL-17. We suggest
that the HLXL-induced increase in IFN-γ inhibits the IL-17
response, which in turn cooperates with the enhanced IL-
10 response to downmodulate the severity of inﬂammatory
arthritis in LEW rats. At present, we do not know the precise
mechanism by which HLXL suppresses the IL-17 response.
Nevertheless, the results of our current study combined
with the recently reported success of a derivative of theEvidence-Based Complementary and Alternative Medicine 7
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Figure 6:AschematicrepresentationofthediversemechanismsinvolvedinHLXL-inducedimmunomodulationofadjuvantarthritis.HLXL
suppressed arthritis via the induction of disease-regulating cytokines coupled with the inhibition of pathogenic events that facilitated the
initiation and propagation of arthritis. (∗IFN-γ has a dual role in autoimmunity.)
plant alkaloid febrifugine in inhibiting the diﬀerentiation of
Th17 cells and suppressing autoimmunity [53] highlight the
signiﬁcance of deﬁning the mechanisms of action of CAM
products for fully exploiting their therapeutic potential.
The above-mentioned HLXL-induced changes involve
the cytokines produced primarily by the T cells. We also
examined the eﬀect of HLXL on two of the major arthritis-
related cytokines (IL-1β and TNF-α) produced by the
synovial tissue from the joints of arthritic mice and rats [54–
57]. Macrophage is one of the main cell types producing
these two cytokines. Our results showed that HLXL feeding
signiﬁcantly reduced the levels of IL-1β but without much
eﬀect on TNF-α. Although both of these cytokines have been
shown to play a major role in the pathogenesis of RA [3, 57,
58], HLXL feeding induced a diﬀerential eﬀect on the two
cytokines in AA. IL-1β induces a cascade of inﬂammatory
reactions that eventually lead to tissue damage. The blocking
of IL-1β by immunochemicals (e.g., anticytokine antibody)
isbeingexploredasatherapeuticapproachforRA[3,57,58].
In this regard, the results showing HLXL-induced inhibition
of the IL-1β production are of signiﬁcance.
Arthritic LEW rats develop not only T cell response to
Bhsp65 but also antibodies to the same antigen [31, 38].
Antibodies play an important role in the development of
arthritis in CIA and K/BXN model of arthritis [59–63],
but the role of antibodies in the initiation or propagation
of AA is not yet clear. Our results show that HLXL-fed
rats had a signiﬁcant reduction both in the titers of anti-
Bhsp65 antibodies and the severity of arthritis on d 19 after
disease induction. These results using HLXL in a therapeutic
regimen in AA are supported by the results of two of
our previous studies based on a preventive regimen for
AA, one using green tea [64] and the other using HLXL
[65]. We suggest that HLXL has an inhibitory eﬀect on
the production of a potentially disease-promoting subset
of antibodies, which might mediate their pathogenic eﬀect,
for example, via activation of the complement pathway
[62, 63]. However, at present, it is not clear whether a
reduced antibody response of HLXL-fed rats contributes
directly or indirectly to the reduced arthritic severity, or it
simply reﬂects an epiphenomenon whereby HLXL feeding
reduces the production of antibodies but without any eﬀect
on disease severity.
HLXL feeding to LEW rats reduced the levels of serum
NO which is one of the biochemical mediators of inﬂamma-
tion [55, 66–68]. NO has been shown to have a pathogenic
role in the development of arthritis in animal models as
well as RA patients [55, 66–68]. In our study, the timing of
maximal inhibition of NO levels directly correlated with that
of the signiﬁcant reduction in the severity of AA. However, at
present,itis not clearwhetherNO is thecauseortheeﬀectof
reduced arthritis severity in HLXL-fed rats. Nevertheless, the
results suggest that NO might serve as one of the biomarkers
for monitoring the anti-inﬂammatory eﬀects of HLXL in
vivo in the AA model.
We observed suppression of arthritis in rats treated with
HLXL beginning on d 12 after disease induction and then
continuing daily HLXL feeding throughout the rest of the
course of arthritis. Typically, in control rats treated with
vehicle alone, the severity of arthritis peaked around d
16 followed by a gradual, spontaneous decline in disease
severity after another 3-4 days. Considering the component
of spontaneous recoveryof clinical arthritis in theAA model,
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relative eﬃcacy of HLXL in preventing the development of
peak arthritic symptoms owing to an early (starting HLXL
feeding on d 12) intervention versus that in suppressing
arthritis at the peak phase of the disease following a late
intervention (starting on d 16). Similarly, the comparative
antiarthritic activity of the herbal mixture versus that of
its individual component herbs remains to be determined.
HLXL consists of 11 component herbs, some of which
have been used individually or in diﬀerent combinations in
TCM for the treatment of arthritis and other inﬂammatory
conditions [24, 25]. One notable component among these
is represented by Boswellia carterii or a related species and
its bioactive chemical constituents, boswellic acids, which
we have previously shown to possess anti-inﬂammatory and
antiarthritic activity [69] and to induce cytokine deviation
to the Th2 type [70]. It is likely that there are additional
chemical constituents besides the boswellic acids within
HLXL that not only contribute to its anti-inﬂammatory and
antiarthritic activity, but also help in limiting the toxicity
of the herbal mixture. In TCM, the relative proportion of
diﬀerentcomponentsofaherbalmixtureisaimedatderiving
a formula that has optimal eﬃcacy but minimal side eﬀects.
Moreover, there might be unique combination eﬀects of the
component herbs in a herbal mixture [71, 72].
In summary, HLXL, a traditional Chinese medicine-
based CAM modality, has therapeutic antiarthritic activity as
tested in the rat AA model. The HLXL-induced inhibition
of ongoing AA involved signiﬁcant changes in the cellular
as well as humoral immune responses to the disease-related
antigen, Bhsp65 (Figure 6). Notably, HLXL feeding caused
suppression of the proinﬂammatory cytokines IL-17 and
IL-1β along with upregulation of the anti-inﬂammatory
cytokine IL-10. Also, there was attenuation of the anti-
Bhsp65 antibody response and reduction in the level of NO,
a known mediator of inﬂammation. On the basis of our
resultsintheAAmodel,wesuggestthatHLXLisapromising
therapeutic agent that should be tested further in preclinical
trials in RA patients.
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